Cannabis Sativa Inc (OTCBB:CBDS) has heated up in a big way and is making a spectacular move up on record volume as pot stocks have ignited after GW Pharmaceuticals announced positive Phase 3 trial data for its drug Epidiolex, for the treatment of Dravet syndrome.
The news is a game changer for pot stocks especially CBDS with several irons of their own in the fire as it proves that cannabinoids can produce compelling and clinical important data and represent a highly promising new class of medications.
Cannabis Sativa Inc (OTCBB:CBDS) is a holding Company in the pot sector with a number of subsidiaries including Hi Brands International, Inc., a Nevada corporation that recently opened its first “Hi” branded marijuana dispensary on October, 2015 in Portland, Oregon.
According to CBDS CEO Gary Johnson “The “Hi” brand aims to help consumers find reliable, trustworthy products in the fast growing but highly fragmented cannabis industry. There is no dominant national brand, no standard bearer. Cannabis Sativa is poised to dominate the industry with the “Hi” brand the way Apple leads the electronics and smart phone space.”
Mr. Johnson cited a recent report in the Huffington Post stating: “Researchers found that the U.S. market for legal cannabis grew 74 percent in 2014 to $2.7 billion”, demonstrating the opportunity for “Hi” Brands International, Inc. “In the last year, the rise of the cannabis industry went from an interesting cocktail conversation to being taken seriously as the fastest growing industry in America,” stated the executive summary of the report. “At this point, it’s hard to imagine that any serious businessperson who is paying attention hasn’t spent some time thinking about the possibilities in this market.”
The “Hi” brand management and marketing solution will give dispensary and retail store owners the management and marketing tools for success in return for an affordable annual fixed license fee or other fixed periodic license fee in accordance with applicable state laws or, where allowed by state law, a royalty on sales.
To Find out the inside Scoop on CBDS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
CDBS hit the bb’s in December 2013 at around $0.75 a share and quickly became one of the top most traded stocks on the entire exchange making a spectacular run to highs of $18 a share as pot stocks ruled the bb’s. CBDS collapsed with the rest of sector in March after the CANN halt and has been dropping since.
The shell was incorporated under the laws of the State of Nevada on November 5, 2004 as Ultra Sun Corp. the Company operated a tanning salon business which they ended up selling in September 2013, In November the Company changed their name to Cannabis Sativa, Inc., and a new pot stock was born.
Cannabis Sativa has had some big names behind it from the beginning; Chairman of the Company Steven Wynn “Steve” Kubby is a Libertarian Party activist who played a key role in the drafting and passage of California Proposition 215, a ballot initiative to legalize medical marijuana which was approved by voters in 1996.
Mr. Kubby himself is a cancer patient and relies on medical MJ. He has written 2 books called the Politics of Consciousness and Why Marijuana Should Be Legal. In the past a number of media outlets reported Mr. Kubby as a felon but his legal statues was resolved on July 3, 2008, when a California Superior Court Judge dismissed all charges against him.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $7 million market valuation CBDS has minimal assets or revenues and growing debt. But CBDS is an exciting story in small caps focused on dominating the pot industry with its “Hi” brand the way Apple leads the electronics and smart phone space. CBDS saw a spectacular rise the last time pot stocks heated up to $18 a share and is leading the flock again following GW Pharmaceuticals positive Phase 3 trial data for its drug Epidiolex. We will be updating on CBDS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CBDS.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in CBDS either long or short and we have not been compensated for this article.